Drug Approval | May 12, 2022
OvaCis rapid test to detect ovarian cancer gets CE mark
Revolutionary ovarian cancer rapid test available Q4 2022
Revolutionary ovarian cancer rapid test available Q4 2022
The company exports mobile surgery equipment to over 100 countries from Pune
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
The company also raised Rs 270 crore investment from Temasek in 2019
The unit is an oral manufacturing facility at Jedcherla, Hyderabad
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
This ANDA has been co-developed in partnership with Orbicular Pharmaceutical Technologies
The new logo is a refreshing change from the version that has served Hetero well for three decades. And yet its reflection can be seen in the new version
Nirsevimab is the first investigational immunization designed to protect all infants across the RSV season with a single dose
The partners also aim to expand their work to Latin America for the first time
Subscribe To Our Newsletter & Stay Updated
